NZ753142A - Inhibitors of glucocorticoid receptor - Google Patents

Inhibitors of glucocorticoid receptor

Info

Publication number
NZ753142A
NZ753142A NZ753142A NZ75314217A NZ753142A NZ 753142 A NZ753142 A NZ 753142A NZ 753142 A NZ753142 A NZ 753142A NZ 75314217 A NZ75314217 A NZ 75314217A NZ 753142 A NZ753142 A NZ 753142A
Authority
NZ
New Zealand
Prior art keywords
compositions
inhibitors
compound
glucocorticoid receptor
useful
Prior art date
Application number
NZ753142A
Other languages
English (en)
Inventor
Xiaohui Du
Lawrence R Mcgee
Daqing Sun
Liusheng Zhu
Xuelei Yan
Yosup Rew
John Eksterowicz
Julio C Medina
Valeria R Fantin
Haiying Zhou
Minna Delarae Balbas
Original Assignee
Oric Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oric Pharmaceuticals Inc filed Critical Oric Pharmaceuticals Inc
Publication of NZ753142A publication Critical patent/NZ753142A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/008Ketals at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J31/00Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J51/00Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • C07J71/0015Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ753142A 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor NZ753142A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662405801P 2016-10-07 2016-10-07
US201762526331P 2017-06-28 2017-06-28
PCT/US2017/055660 WO2018068021A1 (en) 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor

Publications (1)

Publication Number Publication Date
NZ753142A true NZ753142A (en) 2020-08-28

Family

ID=61832215

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ753142A NZ753142A (en) 2016-10-07 2017-10-06 Inhibitors of glucocorticoid receptor

Country Status (20)

Country Link
US (5) US10472387B2 (enExample)
EP (2) EP3851444A1 (enExample)
JP (2) JP6801093B2 (enExample)
KR (2) KR102237916B1 (enExample)
CN (2) CN111690031B (enExample)
AU (3) AU2017339510B2 (enExample)
BR (1) BR112019006987B1 (enExample)
CA (1) CA3039636C (enExample)
DK (1) DK3523315T3 (enExample)
ES (1) ES2867853T3 (enExample)
HU (1) HUE054542T2 (enExample)
IL (2) IL265835B (enExample)
MX (2) MX385658B (enExample)
NZ (1) NZ753142A (enExample)
PL (1) PL3523315T3 (enExample)
PT (1) PT3523315T (enExample)
SG (1) SG11201903055UA (enExample)
SI (1) SI3523315T1 (enExample)
WO (1) WO2018068021A1 (enExample)
ZA (1) ZA202004440B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
EP3394078A4 (en) 2015-12-23 2019-11-27 Oric Pharmaceuticals, Inc. INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
JP6995757B2 (ja) 2015-12-23 2022-01-17 オリック ファーマシューティカルズ,インク. グルココルチコイド受容体の阻害剤
PL3523315T3 (pl) 2016-10-07 2021-10-18 Oric Pharmaceuticals, Inc. Inhibitor receptora glukokortykoidowego
KR20210000719A (ko) * 2018-04-11 2021-01-05 오릭 파마슈티칼스, 인크. 글루코코르티코이드 수용체 길항제를 포함하는 고체 형태 및 제제 및 그의 용도
WO2021163273A1 (en) * 2020-02-12 2021-08-19 Oric Pharmaceuticals, Inc. Uses of glucocorticoid receptor antagonists
WO2021226465A1 (en) * 2020-05-08 2021-11-11 Trustees Of Dartmouth College Glucocorticoid receptor modulators
CN115915529A (zh) 2021-09-30 2023-04-04 赛万特科技有限责任公司 发光控制方法、发光控制装置及发光装置
CN114230627B (zh) * 2021-12-31 2023-09-15 湖南新合新生物医药有限公司 一种倍他米松环氧水解物中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) * 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
BE1004905A4 (fr) 1987-12-30 1993-02-23 Roussel Uclaf Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
JPH02188599A (ja) 1988-11-16 1990-07-24 Roussel Uclaf 3―ケト―デルタ―4,9―19―ノルステロイドから誘導される新物質及びそれらよりなる薬剤
DE3921059A1 (de) * 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
FR2651435A1 (fr) 1989-09-07 1991-03-08 Roussel Uclaf Nouvelle utilisation de composes anti-progestomimetiques.
DE4018167A1 (de) * 1990-06-01 1991-12-05 Schering Ag Verfahren zur herstellung von 10(beta)-h-steroiden
DE4042007A1 (de) * 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
DE69413829T2 (de) 1993-08-04 1999-04-15 Akzo Nobel N.V., Arnheim/Arnhem Antiglucocorticoidsteroide zur behandlung von angststörungen
WO1995017192A1 (en) 1993-12-22 1995-06-29 The Salk Institute For Biological Studies Methods for reducing multidrug resistance
CA2186953C (en) 1995-02-02 2009-11-10 Kristof Chwalsz Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
IL122740A (en) 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
CN1085078C (zh) * 1998-01-07 2002-05-22 沈志华 用于大月份引产的复合药物
US6512130B1 (en) * 2000-09-05 2003-01-28 Council Of Scientific And Industrial Research Mifepristone analogue, process for the preparation thereof and use thereof
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
US7250408B2 (en) * 2002-12-16 2007-07-31 Bayer Schering Pharma Ag Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility
PT1989218E (pt) 2006-02-17 2010-02-01 Janssen Pharmactuica N V Derivados de 17-fósforo esteróides úteis como moduladores do receptor da progesterona
NZ572374A (en) 2006-03-29 2011-12-22 Univ California Diarylthiohydantoin compounds
EP2148681B1 (en) 2007-04-20 2016-03-16 PregLem S.A. Selective progesterone modulators in the treatment of uterine bleeding
EP2671086B1 (en) 2011-02-03 2018-04-25 Pop Test Oncology LLC System and method for diagnosis and treatment
EP2545922A1 (en) 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
US20130029953A1 (en) 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
WO2013126581A1 (en) 2012-02-24 2013-08-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonism and prostate cancer
EP2641602A1 (en) 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
CA2933590C (en) * 2013-12-11 2023-10-03 Sloan-Kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
CN104530166B (zh) 2014-12-04 2016-08-24 陕西汉江药业集团股份有限公司 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法
EP3394078A4 (en) * 2015-12-23 2019-11-27 Oric Pharmaceuticals, Inc. INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
WO2017112904A1 (en) 2015-12-23 2017-06-29 Oric Pharmaceuticals, Inc. Inhibitors of glucocorticoid receptor
JP6995757B2 (ja) * 2015-12-23 2022-01-17 オリック ファーマシューティカルズ,インク. グルココルチコイド受容体の阻害剤
PL3523315T3 (pl) 2016-10-07 2021-10-18 Oric Pharmaceuticals, Inc. Inhibitor receptora glukokortykoidowego
WO2018227129A1 (en) 2017-06-09 2018-12-13 Regents Of The University Of Minnesota Skin care formulations and skin cancer treatment
KR20210000719A (ko) 2018-04-11 2021-01-05 오릭 파마슈티칼스, 인크. 글루코코르티코이드 수용체 길항제를 포함하는 고체 형태 및 제제 및 그의 용도

Also Published As

Publication number Publication date
AU2021202016C1 (en) 2022-06-09
EP3523315B1 (en) 2021-03-24
MX385658B (es) 2025-03-18
CA3039636A1 (en) 2018-04-12
CN111690031A (zh) 2020-09-22
US20230096870A1 (en) 2023-03-30
IL265835A (en) 2019-06-30
US20200055892A1 (en) 2020-02-20
EP3523315A1 (en) 2019-08-14
MX2021010252A (es) 2021-09-21
AU2020213316B2 (en) 2021-03-11
AU2020213316A1 (en) 2020-08-27
US10472387B2 (en) 2019-11-12
EP3851444A1 (en) 2021-07-21
ES2867853T3 (es) 2021-10-21
CN111690031B (zh) 2021-06-01
KR102237916B1 (ko) 2021-04-09
US20190218246A1 (en) 2019-07-18
MX2019004030A (es) 2019-09-16
PT3523315T (pt) 2021-04-29
EP3523315A4 (en) 2020-04-15
SI3523315T1 (sl) 2021-08-31
PL3523315T3 (pl) 2021-10-18
JP6801093B2 (ja) 2020-12-16
AU2021202016B2 (en) 2022-01-06
ZA202004440B (en) 2022-07-27
US10836789B2 (en) 2020-11-17
DK3523315T3 (da) 2021-05-03
HUE054542T2 (hu) 2021-09-28
AU2021202016A1 (en) 2021-04-29
JP2019533651A (ja) 2019-11-21
IL284005A (en) 2021-07-29
CN110099915A (zh) 2019-08-06
JP2021046409A (ja) 2021-03-25
BR112019006987A2 (pt) 2019-06-25
CA3039636C (en) 2023-04-11
AU2017339510A1 (en) 2019-05-23
KR20210039001A (ko) 2021-04-08
US20200291058A1 (en) 2020-09-17
KR20190083651A (ko) 2019-07-12
IL265835B (en) 2021-06-30
US10723759B2 (en) 2020-07-28
AU2017339510B2 (en) 2020-07-30
WO2018068021A1 (en) 2018-04-12
US20210017219A1 (en) 2021-01-21
SG11201903055UA (en) 2019-05-30
BR112019006987B1 (pt) 2021-05-04

Similar Documents

Publication Publication Date Title
NZ753142A (en) Inhibitors of glucocorticoid receptor
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
PH12016502179A1 (en) Inhibitors of lysine specific demethylase-1
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12018500981A1 (en) Treatment of osteoarthritis
SG11201806348PA (en) Steroid derivative fxr agonist
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
TW201613895A (en) Phosphatidylinositol 3-kinase inhibitors
NZ726608A (en) Phosphatidylinositol 3-kinase inhibitors
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX363127B (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
NZ726360A (en) Phosphatidylinositol 3-kinase inhibitors
MX386089B (es) Compuesto heterociclico utilizado como inhibidor de fgfr.
NZ726638A (en) Phosphatidylinositol 3-kinase inhibitors
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MY197698A (en) Oxysterols and methods of use thereof
MX2016016538A (es) Derivados de quinazolinona como inhibidores de fosfatidilinositol 3-cinasa.
PH12020550442A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
MX2016014946A (es) Derivados de carboxamida.
PH12022550497A1 (en) Perk inhibiting compounds
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201990859A1 (ru) Ингибиторы глюкокортикоидного рецептора
PH12016502281A1 (en) Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2022 BY COMPUTER PACKAGES INC

Effective date: 20210917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2023 BY COMPUTER PACKAGES INC

Effective date: 20220917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2024 BY COMPUTER PACKAGES INC

Effective date: 20230917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2025 BY COMPUTER PACKAGES INC

Effective date: 20240917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 OCT 2026 BY COMPUTER PACKAGES INC

Effective date: 20250917